ifosfamide and Thrombocytopenia studies

Research Excerpts

Excerpt	Relevance	Reference
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."	9.17	Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."	9.11	Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."	9.11	Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."	9.10	Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."	9.10	Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	9.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."	9.08	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma."	9.07	A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."	7.81	[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin."	7.73	[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."	7.70	[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."	7.69	Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."	7.68	Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."	6.68	Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."	5.17	Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."	5.11	Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."	5.11	Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles."	5.10	Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. ( Benjamin, RS; Broemeling, LD; Broxmeyer, HE; Bueso-Ramos, C; Burgess, A; Folloder, J; Papadopolous, N; Patel, S; Vadhan-Raj, S, 2003)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."	5.10	Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."	5.10	Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"Twenty-nine patients diagnosed with recurrent neuroblastoma or PNET were treated with a combination chemotherapy regimen of cisplatin, 160 mg/m(2)/96 hours; doxorubicin, 40 mg/m(2)/96 hours; and escalated doses of etoposide and ifosfamide."	5.09	A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. ( Fernandez, MC; Gerbing, RR; Krailo, MD; Matthay, KK, 2000)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."	5.08	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	5.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
" At the original dose of cisplatin, etoposide, and ifosfamide without G-CSF, 55% of cycles resulted in neutropenia and 38% in thrombocytopenia (dose intensity = 0."	5.08	Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. ( Fanning, J; Hilgers, RD, 1996)
"This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma."	5.07	A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."	3.81	[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded."	3.78	Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012)
"The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades."	3.77	Neoadjuvant therapy for cervical cancer. ( Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG, 1992)
"Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin."	3.73	[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."	3.70	[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."	3.69	Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)."	3.68	[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."	3.68	Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma."	2.87	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. ( Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A, 2018)
"Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial."	2.75	Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. ( Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG, 2010)
" Sequential dose intense ifosfamide, etoposide, carboplatin +/- rituximab was more toxic and no more effective than the same drugs given in a conventional fashion."	2.74	Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. ( Beaven, AW; Chao, N; Gabriel, DA; Garcia, RA; Gockerman, JP; Moore, DT; Rizzieri, DA; Serody, JS; Shea, TC, 2009)
"Neutropenia was the major toxicity."	2.71	Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004)
"Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients."	2.71	Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005)
"Grade 3 thrombocytopenia was observed in five cases (36%)."	2.71	Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
"To find the maximum tolerated dose for ifosfamide in combination with paclitaxel and carboplatin in small-cell lung cancer patients (SCLC), who are resistant to cyclophosphamide, doxorubicin and etoposide (CDE)."	2.70	Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. ( Beijnen, JH; Groen, HJ; Kerbush, T; Sleijfer, DT; Smit, EF; van Putten, JW; van Rijswijk, R, 2001)
"Grade 3-4 neutropenia was experienced by 9 (27%) patients, grade 3 4 anemia by 6 (18%) and grade 3-4 thrombocytopenia by 4 (12%)."	2.70	Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001)
" Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone."	2.69	Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000)
" We report the use of a continuous high dose infusion of ïfosfamide at a dose of 9g/m(2) over 3 days in combination with etoposide and epirubicin followed by autologous stem cell transplant with either BEAM or Melphalan/VP16 conditioning in this difficult group."	2.69	High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K, 2000)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."	2.68	Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
" The dosage of paclitaxel was escalated from 75 to 225 mg/m2."	2.68	A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. ( Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ, 1995)
"Twenty-three patients with chronic myelogenous leukemia in early chronic phase (ECP) and not previously treated with alpha-interferon (IFN-alpha) (10 patients), in ECP but pretreated with IFN-alpha (<12 months) (seven patients) and in late chronic phase (LCP) pretreated with IFN-alpha (>12 months) (six patients) underwent autografting with Philadelphia (Ph) chromosome-negative blood progenitor cells (BPCs) (20 patients), or partially/totally Ph-positive BPCs (three patients), previously mobilized during the early phase of recovery after aplasia induced by intensive chemotherapy."	2.68	High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. ( Benvenuto, F; Carella, AM; Carlier, P; Chimirri, F; Dejana, A; Ferrara, RA; Florio, G; Frassoni, F; Gatti, AM; Incagliato, M; Lerma, E; Piaggio, G; Pitto, A; Podestà, M; Pollicardo, N; Prencipe, E; Soracco, M; Valbonesi, M; Vassallo, F; Vimercati, R, 1996)
"The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors."	2.67	Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ( Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J, 1993)
"Paclitaxel is a potent anticancer agent against a variety of solid cancers."	1.33	[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. ( Kawauchi, A; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Nakanishi, H; Nomoto, T, 2006)
"Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)."	1.33	IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005)
"Febrile neutropenia was observed in 5 patients (41."	1.32	[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer]. ( Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H, 2004)
"Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients."	1.29	Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996)

Research

Studies (84)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (4.76)	18.7374
1990's	31 (36.90)	18.2507
2000's	35 (41.67)	29.6817
2010's	11 (13.10)	24.3611
2020's	3 (3.57)	2.80

Authors	Studies
Zhang, B	2
Zhang, Y	2
Li, R	1
Li, J	1
Lu, X	1
Sang, W	1
Shi, M	1
Yang, J	2
Cao, J	1
Xu, L	1
Yan, D	1
Yao, M	1
Liu, H	1
Li, W	2
Sun, K	1
Song, X	1
Sun, C	1
Jiao, J	1
Qin, Y	2
Sang, T	1
Ma, Y	1
Wu, M	1
Gao, X	1
Cheng, H	1
Yan, Z	1
Li, D	1
Sun, H	1
Zhu, F	1
Wang, Y	1
Zeng, L	1
Li, Z	1
Zheng, J	1
Xu, K	1
Rainusso, N	1
Gruner, SE	1
Hernandez, JA	1
Hu, B	1
Younes, A	1
Westin, JR	1
Turturro, F	1
Claret, L	1
Feng, L	1
Fowler, N	1
Neelapu, S	1
Romaguera, J	1
Hagemeister, FB	1
Rodriguez, MA	1
Samaniego, F	1
Fayad, LE	1
Copeland, AR	1
Nastoupil, LJ	1
Nieto, Y	1
Fanale, MA	1
Oki, Y	1
Chawla, SP	1
Staddon, A	1
Hendifar, A	1
Messam, CA	1
Patwardhan, R	1
Kamel, YM	1
Evens, AM	1
Carson, KR	1
Kolesar, J	1
Nabhan, C	1
Helenowski, I	1
Islam, N	1
Jovanovic, B	1
Barr, PM	1
Caimi, PF	1
Gregory, SA	1
Gordon, LI	1
Kakutani, S	1
Fukuhara, H	1
Taguchi, S	1
Nagata, M	1
Niimi, A	1
Hattori, M	1
Miyazaki, H	1
Fujimura, T	1
Nakagawa, T	1
Kume, H	2
Igawa, Y	1
Homma, Y	1
Fayad, L	1
Ansell, SM	1
Advani, R	1
Coiffier, B	1
Stuart, R	1
Bartlett, NL	1
Forero-Torres, A	1
Kuliczkowski, K	1
Belada, D	1
Ng, E	1
Drachman, JG	1
Yin, ZM	1
Yu, AJ	1
Wu, MJ	1
Fang, J	1
Liu, LF	1
Zhu, JQ	1
Yu, H	1
Hu, S	1
He, X	1
Dong, M	2
Jia, B	1
Zhou, S	1
Yang, S	2
Zhang, C	1
Liu, P	2
Gui, L	1
Liu, XM	1
Wang, HQ	1
Zhang, HL	1
Qiu, LH	1
Li, LF	1
Cui, XZ	1
Liu, PF	1
Hao, XS	1
Shea, TC	1
Beaven, AW	1
Moore, DT	1
Serody, JS	1
Gabriel, DA	1
Chao, N	1
Gockerman, JP	1
Garcia, RA	1
Rizzieri, DA	1
Sun, XF	2
Zhen, ZJ	2
Xiang, XJ	1
Ling, JY	2
Peng, RJ	1
Xia, Y	2
Zheng, L	1
Luo, WB	1
Lin, H	1
Guan, ZZ	1
Specenier, P	1
Rasschaert, M	1
Van den Brande, J	1
Dyck, J	1
Schrijvers, D	2
Huizing, MT	1
Vermorken, JB	1
Levin, RD	1
Daehler, M	1
Grutsch, JF	1
Hall, JL	1
Gupta, D	1
Lis, CG	1
Hong, S	1
Shin, SJ	1
Jung, M	1
Jeong, J	1
Lee, YJ	1
Shin, KH	1
Roh, JK	1
Rha, SY	1
Gupta, AA	1
Anderson, JR	1
Pappo, AS	1
Spunt, SL	1
Dasgupta, R	1
Indelicato, DJ	1
Hawkins, DS	1
Blot, E	1
Decaudin, D	1
Veyradier, A	1
Bardier, A	1
Zagame, OL	1
Pouillart, P	1
Arellano-Rodrigo, E	1
López-Guillermo, A	1
Bessell, EM	1
Nomdedeu, B	1
Montserrat, E	1
Graus, F	1
Vadhan-Raj, S	2
Patel, S	1
Bueso-Ramos, C	1
Folloder, J	1
Papadopolous, N	1
Burgess, A	1
Broemeling, LD	1
Broxmeyer, HE	1
Benjamin, RS	1
Suzuki, S	1
Shinohara, N	1
Harabayashi, T	1
Seki, H	1
Murakumo, M	1
Ishikawa, R	1
Demura, T	1
Mitsuhashi, K	1
Toyota, H	1
Koyanagi, T	1
Kerbusch, T	1
Groenewegen, G	1
Mathôt, RA	1
Herben, VM	1
ten Bokkel Huinink, WW	1
Swart, M	1
Ambaum, B	1
Rosing, H	1
Jansen, S	1
Voest, EE	1
Beijnen, JH	2
Schellens, JH	1
Fiegl, M	1
Schlemmer, M	1
Wendtner, CM	1
Abdel-Rahman, S	1
Fahn, W	1
Issels, RD	1
Cairo, MS	2
Davenport, V	1
Bessmertny, O	1
Goldman, SC	1
Berg, SL	1
Kreissman, SG	1
Laver, J	1
Shen, V	1
Secola, R	1
van de Ven, C	1
Reaman, GH	1
Worden, FP	1
Taylor, JM	1
Biermann, JS	1
Sondak, VK	1
Leu, KM	1
Chugh, R	1
McGinn, CJ	1
Zalupski, MM	1
Baker, LH	1
Takahashi, S	1
Suzuki, M	1
Matsumoto, S	1
Okamoto, N	1
Nishimatsu, H	1
Tomita, K	1
Kitamura, T	1
Zhou, SY	1
Shi, YK	1
He, XH	1
Zhang, P	1
Huang, DZ	1
Yang, JL	1
Zhang, CG	1
Feng, FY	1
Abali, H	1
Oyan, B	1
Koc, Y	1
Kars, A	1
Barista, I	1
Uner, A	1
Turker, A	1
Demirkazik, F	1
Tekin, F	1
Tekuzman, G	1
Kansu, E	1
Chamorey, E	1
Gressin, R	1
Peyrade, F	1
Rossi, JF	2
Lepeu, G	1
Foussard, C	1
Harrousseau, JL	1
Fabbro, M	1
Richard, B	1
Delwail, V	1
Maisonneuve, H	1
Vilque, JP	1
Thyss, A	1
Lorusso, V	2
Gebbia, V	1
Spada, M	1
Guida, M	1
Cassano, G	1
Brunetti, C	1
Germano, D	1
Nettis, G	1
Izzi, G	1
Galetta, D	1
Giampaglia, M	1
Silvestris, N	1
Colucci, G	1
Fan, Y	1
Huang, ZY	1
Luo, LH	1
Yu, HF	1
Nomoto, T	1
Mizutani, Y	1
Mikami, K	1
Nakamura, T	1
Nakanishi, H	1
Kawauchi, A	1
Miki, T	1
Li, EX	1
Zhang, YT	1
Shang, JT	1
Xu, Z	1
Geng, Y	1
Li, SM	1
Shi, F	1
Wu, YY	1
Wang, ZH	1
Bo, LJ	1
Liang, AB	1
Liu, B	1
Chen, YH	1
Wang, F	1
Jin, XP	1
Morgan, LR	1
Harrison, EF	1
Hawke, JE	1
Hunter, HL	1
Costanzi, JJ	1
Plotkin, D	1
Tucker, WG	1
Worrall, PM	1
Beyer, J	1
Schwella, N	1
Zingsem, J	1
Strohscheer, I	1
Schwaner, I	1
Oettle, H	1
Serke, S	1
Huhn, D	1
Stieger, W	1
Saeter, G	1
Talle, K	1
Solheim, OP	1
Crawford, J	1
George, M	1
Haim, N	1
Ben-Shahar, M	1
Epelbaum, R	1
Strauss, GM	1
Lynch, TJ	1
Elias, AD	1
Jacobs, C	1
Kwiatkowski, DJ	1
Shulman, LN	1
Carey, RW	1
Grossbard, ML	1
Jauss, S	1
Sugarbaker, DJ	1
Santoro, A	2
Tursz, T	1
Mouridsen, H	1
Verweij, J	2
Steward, W	1
Somers, R	2
Buesa, J	1
Casali, P	1
Spooner, D	1
Rankin, E	1
Dirix, LY	1
van Meerbeeck, J	1
Corthouts, B	1
Prové, A	1
van Marck, E	1
Vermeire, P	1
van Oosterom, AT	2
Bokemeyer, C	1
Schmoll, HJ	1
Harstrick, A	1
Illiger, HJ	1
Metzner, B	1
Räth, U	1
Hohnloser, J	1
Clemm, C	1
Berdel, W	1
Siegert, W	1
Filtenborg, TA	1
Hansen, HH	2
Aage Engelholm, S	1
Rørth, M	1
Graziano, SL	1
Herndon, JE	1
Richards, F	1
DiFino, S	1
Modeas, C	1
Duggan, DB	1
Green, MR	1
Marina, NM	1
Rodman, J	1
Shema, SJ	1
Bowman, LC	1
Douglass, E	1
Furman, W	1
Santana, VM	1
Hudson, M	1
Wilimas, J	1
Meyer, W	1
Magrath, I	1
Adde, M	1
Shad, A	1
Venzon, D	1
Seibel, N	1
Gootenberg, J	1
Neely, J	1
Arndt, C	1
Nieder, M	1
Jaffe, E	1
Wittes, RA	1
Horak, ID	1
Carella, AM	1
Chimirri, F	1
Podestà, M	1
Pitto, A	1
Piaggio, G	1
Dejana, A	1
Lerma, E	1
Pollicardo, N	1
Vassallo, F	1
Soracco, M	1
Benvenuto, F	1
Valbonesi, M	1
Carlier, P	1
Vimercati, R	1
Prencipe, E	1
Gatti, AM	1
Ferrara, RA	1
Incagliato, M	1
Florio, G	1
Frassoni, F	1
Chang, AY	1
Boros, L	1
Garrow, GC	1
Asbury, RF	1
Hui, L	1
Lokich, J	1
Anderson, N	1
Moore, C	1
Bern, M	1
Coco, F	1
Dow, E	1
Wexler, LH	1
DeLaney, TF	1
Tsokos, M	1
Avila, N	1
Steinberg, SM	1
Weaver-McClure, L	1
Jacobson, J	1
Jarosinski, P	1
Hijazi, YM	1
Balis, FM	1
Horowitz, ME	1
Fanning, J	1
Hilgers, RD	1
Glisson, B	2
Lee, JS	2
Palmer, J	1
Fossella, F	2
Shin, DM	2
Murphy, WK	2
Perez-Soler, R	2
Hong, WK	1
Komaki, R	1
Kurie, J	1
Schea, R	1
Hirota, T	1
Takeuchi, M	1
Iwata, A	1
Kitagawa, S	1
Sato, T	1
Konno, K	1
Sawada, K	1
Kobayashi, S	1
Hamaguchi, N	1
Agata, H	1
Katano, N	1
Fujimoto, T	1
Leone, B	1
Di Vagno, G	1
Manzione, L	1
Palmeri, S	1
Vallejo, C	1
Machiavelli, M	1
Nacci, G	1
Bilancia, D	1
Leonardi, V	1
Catino, A	1
Gargano, G	1
Loverro, G	1
Selvaggi, L	1
De Lena, M	1
De Pas, T	2
De Braud, F	1
Orlando, L	1
Nolè, F	1
Munzone, E	1
Zampino, MG	1
Fazio, N	1
Aapro, MS	1
Goldhirsch, A	1
van de Velde, H	1
Bosquée, L	1
Weynants, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2017-03-01	Recruiting
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540]	Phase 1	18 participants (Actual)	Interventional	2006-06-01	Completed
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma[NCT00392990]	Phase 2	25 participants (Actual)	Interventional	2007-02-06	Completed
A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00529503]	Phase 2	151 participants (Actual)	Interventional	2007-09-30	Terminated
Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy[NCT01163110]	Phase 1	32 participants (Actual)	Interventional	2004-03-31	Completed
Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920]	Phase 2	30 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153]	Phase 2	41 participants (Actual)	Interventional	2010-04-30	Completed
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499]	Phase 2	53 participants (Actual)	Interventional	2010-01-31	Completed
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy[NCT00406601]	Phase 2	69 participants (Actual)	Interventional	2006-11-30	Completed
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2017-11-06	Withdrawn (stopped due to No participants enrolled)
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193]	Phase 2	20 participants (Anticipated)	Interventional	2006-08-31	Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494]	Phase 2	134 participants (Actual)	Interventional	1992-05-31	Completed
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473]	Phase 2	100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason. (NCT00392990)
Timeframe: At 2 years from treatment initiation Median follow up 34 months (range 15-45)

Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Intervention	percentage of patients alive (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	81
Low Risk - Treatment With 3 Cycles of R-CODOX-M	100

Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event. (NCT00392990)
Timeframe: At 2 years from treatment initiation. Median follow up 34 months (range 15-45)

Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Intervention	percentage of patients progression free (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	76
Low Risk - Treatment With 3 Cycles of R-CODOX-M	100

"Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where:~CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms.~CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow.~PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease." (NCT00392990)
Timeframe: After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks.

Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)

Intervention	percentage of patients (Number)
	ORR after two cycles of treatment	ORR at completion of treatment
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	100	100
Low Risk - Treatment With 3 Cycles of R-CODOX-M	100	100

"Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months.~In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following:~Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE" (NCT00392990)
Timeframe: After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients.

Intervention	participants (Number)
	Anemia : Grade 3	Anemia : Grade 4	Neutropenia : Grade 3	Neutropenia : Grade 4	Thrombocytopenia : Grade 3	Thrombocytopenia : Grade 4	Mucositis : Grade 3	Mucositis : Grade 4	Infection : Grade 3	Infection : Grade 4	Elevated Transaminases : Grade 3	Elevated Transaminases : Grade 4	Fever (Neutropenic) : Grade 3	Fever (Neutropenic) : Grade 4	Low Phosphate : Grade 3	Low Phosphate : Grade 4	Sodium Abnormalities : Grade 3	Sodium Abnormalities : Grade 4	Hyperglycemia : Grade 3	Hyperglycemia : Grade 4	Hypoalbuminemia : Grade 3	Hypoalbuminemia : Grade 4	Hypokalemia : Grade 3	Hypokalemia : Grade 4	Cardiac : Grade 3	Cardiac : Grade 4	Diarrhea : Grade 3	Diarrhea : Grade 4	Elevated Creatinine : Grade 3	Elevated Creatinine : Grade 4	Nausea/Vomiting : Grade 3	Nausea/Vomiting : Grade 4	Low Blood Pressure : Grade 3	Low Blood Pressure : Grade 4	Rash : Grade 3	Rash : Grade 4	Edema : Grade 3	Edema : Grade 4	Low Magnesium : Grade 3	Low Magnesium : Grade 4
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	13	1	5	6	1	13	7	3	8	0	6	0	4	0	5	0	4	0	1	5	4	0	1	0	3	0	2	0	2	0	1	0	1	0	1	0	1	0	1	0
Low Risk - Treatment With 3 Cycles of R-CODOX-M	3	0	2	2	1	2	2	0	1	0	2	0	3	0	1	0	2	0	3	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Article	Year
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R	2020
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administ	2018
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC cancer, 2013, Mar-16, Volume: 13 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-	2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2013
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb Leukemia & lymphoma, 2015, Volume: 56, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carb	2015
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro	2008
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & lymphoma, 2009, Volume: 50, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Stu	2009
[Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid	2009
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. Anti-cancer drugs, 2010, Volume: 21, Issue:3 Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries;	2010
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC cancer, 2010, Oct-19, Volume: 10 Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug;	2010
Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-15, Volume: 21, Issue:16 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies	2003
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D	2004
Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th	2004
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. British journal of haematology, 2005, Volume: 128, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch	2005
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant	2005
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2 Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo	2005
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma. Oncology, 2005, Volume: 69, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free	2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncology reports, 2005, Volume: 14, Issue:6 Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-	2005
Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb	1995
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl	1995
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, No	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio	1995
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal	1994
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Granulocyte-Macroph	1993
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	1993
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. Cancer, 1993, Jul-01, Volume: 72, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	1993
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch	1993
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3 Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch	1996
High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone marrow transplantation, 1996, Volume: 17, Issue:2 Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow;	1996
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE). The Journal of infusional chemotherapy, 1996,Winter, Volume: 6, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che	1996
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer, 1996, Aug-15, Volume: 78, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp	1996
Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. Gynecologic oncology, 1996, Volume: 63, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Mod	1996
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer, 1998, Jan-15, Volume: 82, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo	1998
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. International journal of radiation oncology, biology, physics, 1998, Jan-15, Volume: 40, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cohor	1998
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study). Gynecologic oncology, 1998, Volume: 68, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb	1998
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8 Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib	1998
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined M	1999
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients. Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:12 Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ch	1999
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. British journal of cancer, 2000, Volume: 82, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,	2000
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer, 2000, Jun-15, Volume: 88, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati	2000
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC). International journal of cancer, 2000, Sep-01, Volume: 87, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. British journal of cancer, 2000, Volume: 83, Issue:9 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S	2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Leukemia & lymphoma, 2000, Volume: 37, Issue:5-6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirub	2000
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2000, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	2000
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma	2001
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. Medical and pediatric oncology, 2001, Volume: 36, Issue:1 Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi	2001
Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid	2001
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He	2001
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr	2002
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined	2002
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724). European journal of cancer, 1976, Volume: 12, Issue:3 Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul	1976
Neoadjuvant therapy for cervical cancer. Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	1992

Article	Year
Splenic embolization to continue chemotherapy in a child with hypersplenism-related thrombocytopenia. Pediatric blood & cancer, 2021, Volume: 68, Issue:2 Topics: Antineoplastic Agents; Child; Cyclophosphamide; Desmoplastic Small Round Cell Tumor; Doxorubicin; Em	2021
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce	2015
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma. European journal of gynaecological oncology, 2015, Volume: 36, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendo	2015
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:8 Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid	2015
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. Oncology, 2011, Volume: 80, Issue:1-2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre	2011
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer, 2012, Feb-15, Volume: 118, Issue:4 Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc	2012
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency. Thrombosis research, 2002, Apr-15, Volume: 106, Issue:2 Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe	2002
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine	2003
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans;	2004
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha	2005
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F	2005
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo	2005
[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2006, Volume: 97, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sc	2006
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F	2006
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbo	2006
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;	2006
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans;	1982
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F	1995
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen	1996
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms;	1998
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer. Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deo	2001
Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administra	1992
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea	1991
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio	1990
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Com	1990
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	1990
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn	1986
Ifosfamide chemotherapy for pancreatic carcinoma. Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2 Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam	1986

ifosfamide and Thrombocytopenia